Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

BACKGROUND: Melanoma brain metastases (MBMs) are a challenging clinical problem with high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab–nivolumab have similar intracranial response rates (50%–55%), central nervous system (CNS) resistance to BRAF-MEK inhibitors (BR...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Peter Kar Han, Feran, Breon, Smith, Lorey, Lasocki, Arian, Molania, Ramyar, Smith, Kortnye, Weppler, Alison, Angel, Christopher, Kee, Damien, Bhave, Prachi, Lee, Belinda, Young, Richard J, Iravani, Amir, Yeang, Hanxian Aw, Vergara, Ismael A, Kok, David, Drummond, Kate, Neeson, Paul Joseph, Sheppard, Karen E, Papenfuss, Tony, Solomon, Benjamin J, Sandhu, Shahneen, McArthur, Grant A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504361/
https://www.ncbi.nlm.nih.gov/pubmed/34625515
http://dx.doi.org/10.1136/jitc-2021-002995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504361/
https://www.ncbi.nlm.nih.gov/pubmed/34625515
http://dx.doi.org/10.1136/jitc-2021-002995

Ejemplares similares